nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—Cyclobenzaprine—Tamoxifen—pancreatic cancer	0.0634	0.15	CrCrCtD
Imipramine—Doxylamine—Tamoxifen—pancreatic cancer	0.0582	0.138	CrCrCtD
Imipramine—Tripelennamine—Tamoxifen—pancreatic cancer	0.0527	0.125	CrCrCtD
Imipramine—Dimetacrine—Tamoxifen—pancreatic cancer	0.0492	0.116	CrCrCtD
Imipramine—Bromodiphenhydramine—Tamoxifen—pancreatic cancer	0.0492	0.116	CrCrCtD
Imipramine—Clofedanol—Tamoxifen—pancreatic cancer	0.04	0.0946	CrCrCtD
Imipramine—SLC22A3—Irinotecan—pancreatic cancer	0.0399	0.104	CbGbCtD
Imipramine—Orphenadrine—Tamoxifen—pancreatic cancer	0.0387	0.0915	CrCrCtD
Imipramine—Promazine—Tamoxifen—pancreatic cancer	0.0369	0.0874	CrCrCtD
Imipramine—Diphenhydramine—Tamoxifen—pancreatic cancer	0.0344	0.0813	CrCrCtD
Imipramine—ORM1—Erlotinib—pancreatic cancer	0.0316	0.0825	CbGbCtD
Imipramine—CYP2E1—Dacarbazine—pancreatic cancer	0.0203	0.0531	CbGbCtD
Imipramine—KCNH2—Sunitinib—pancreatic cancer	0.0184	0.0479	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0168	0.0437	CbGbCtD
Imipramine—CYP3A7—Tamoxifen—pancreatic cancer	0.0168	0.0437	CbGbCtD
Imipramine—CYP2E1—Tamoxifen—pancreatic cancer	0.0162	0.0422	CbGbCtD
Imipramine—CYP2B6—Tamoxifen—pancreatic cancer	0.016	0.0416	CbGbCtD
Imipramine—CYP3A7—Irinotecan—pancreatic cancer	0.0129	0.0336	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0129	0.0336	CbGbCtD
Imipramine—CYP2B6—Irinotecan—pancreatic cancer	0.0123	0.032	CbGbCtD
Imipramine—CYP1A2—Dacarbazine—pancreatic cancer	0.0118	0.0307	CbGbCtD
Imipramine—CYP2C19—Tamoxifen—pancreatic cancer	0.0101	0.0265	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.00944	0.0246	CbGbCtD
Imipramine—CYP3A7—Docetaxel—pancreatic cancer	0.00944	0.0246	CbGbCtD
Imipramine—CYP3A7—Sunitinib—pancreatic cancer	0.00939	0.0245	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.00939	0.0245	CbGbCtD
Imipramine—CYP1A2—Tamoxifen—pancreatic cancer	0.00936	0.0244	CbGbCtD
Imipramine—ABCB1—Tamoxifen—pancreatic cancer	0.00819	0.0213	CbGbCtD
Imipramine—CYP1A2—Erlotinib—pancreatic cancer	0.00796	0.0208	CbGbCtD
Imipramine—CYP2D6—Tamoxifen—pancreatic cancer	0.00771	0.0201	CbGbCtD
Imipramine—ABCB1—Gemcitabine—pancreatic cancer	0.00705	0.0184	CbGbCtD
Imipramine—ABCB1—Erlotinib—pancreatic cancer	0.00696	0.0182	CbGbCtD
Imipramine—CYP1A2—Fluorouracil—pancreatic cancer	0.0069	0.018	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—pancreatic cancer	0.0067	0.0175	CbGbCtD
Imipramine—CYP2D6—Erlotinib—pancreatic cancer	0.00656	0.0171	CbGbCtD
Imipramine—ABCB1—Irinotecan—pancreatic cancer	0.00629	0.0164	CbGbCtD
Imipramine—CYP3A4—Tamoxifen—pancreatic cancer	0.00491	0.0128	CbGbCtD
Imipramine—ABCB1—Docetaxel—pancreatic cancer	0.00461	0.012	CbGbCtD
Imipramine—ABCB1—Sunitinib—pancreatic cancer	0.00459	0.012	CbGbCtD
Imipramine—CYP3A4—Erlotinib—pancreatic cancer	0.00417	0.0109	CbGbCtD
Imipramine—HTR7—enteric nervous system—pancreatic cancer	0.00403	0.252	CbGeAlD
Imipramine—CYP3A4—Irinotecan—pancreatic cancer	0.00377	0.00982	CbGbCtD
Imipramine—ABCB1—Doxorubicin—pancreatic cancer	0.00343	0.00896	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—pancreatic cancer	0.00324	0.00844	CbGbCtD
Imipramine—ORM1—bile—pancreatic cancer	0.00293	0.183	CbGeAlD
Imipramine—CYP3A4—Docetaxel—pancreatic cancer	0.00276	0.0072	CbGbCtD
Imipramine—CYP3A4—Sunitinib—pancreatic cancer	0.00275	0.00717	CbGbCtD
Imipramine—HTR2A—enteric nervous system—pancreatic cancer	0.00251	0.157	CbGeAlD
Imipramine—CYP3A4—Doxorubicin—pancreatic cancer	0.00206	0.00537	CbGbCtD
Imipramine—KCND3—islet of Langerhans—pancreatic cancer	0.000972	0.0608	CbGeAlD
Imipramine—ORM1—gall bladder—pancreatic cancer	0.000812	0.0508	CbGeAlD
Imipramine—KCND3—pancreas—pancreatic cancer	0.000683	0.0427	CbGeAlD
Imipramine—CYP2C18—digestive system—pancreatic cancer	0.000531	0.0332	CbGeAlD
Imipramine—SLC22A2—digestive system—pancreatic cancer	0.000415	0.0259	CbGeAlD
Imipramine—KCNH2—islet of Langerhans—pancreatic cancer	0.000359	0.0224	CbGeAlD
Imipramine—SLC22A4—digestive system—pancreatic cancer	0.000308	0.0192	CbGeAlD
Imipramine—SLC6A4—digestive system—pancreatic cancer	0.000272	0.017	CbGeAlD
Imipramine—CHRM3—digestive system—pancreatic cancer	0.000243	0.0152	CbGeAlD
Imipramine—HTR7—digestive system—pancreatic cancer	0.000231	0.0145	CbGeAlD
Imipramine—CYP2C19—digestive system—pancreatic cancer	0.000226	0.0141	CbGeAlD
Imipramine—CYP1A2—digestive system—pancreatic cancer	0.000184	0.0115	CbGeAlD
Imipramine—CYP2B6—digestive system—pancreatic cancer	0.000177	0.0111	CbGeAlD
Imipramine—HRH1—digestive system—pancreatic cancer	0.000173	0.0108	CbGeAlD
Imipramine—CYP2E1—digestive system—pancreatic cancer	0.000166	0.0104	CbGeAlD
Imipramine—ABCB1—islet of Langerhans—pancreatic cancer	0.000157	0.00984	CbGeAlD
Imipramine—HTR2A—digestive system—pancreatic cancer	0.000144	0.00902	CbGeAlD
Imipramine—CYP3A4—digestive system—pancreatic cancer	0.000133	0.00835	CbGeAlD
Imipramine—CYP2D6—digestive system—pancreatic cancer	0.000131	0.00821	CbGeAlD
Imipramine—Nausea—Tamoxifen—pancreatic cancer	0.000118	0.00118	CcSEcCtD
Imipramine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000118	0.00118	CcSEcCtD
Imipramine—Fatigue—Gemcitabine—pancreatic cancer	0.000118	0.00118	CcSEcCtD
Imipramine—Constipation—Gemcitabine—pancreatic cancer	0.000117	0.00117	CcSEcCtD
Imipramine—Nausea—Erlotinib—pancreatic cancer	0.000117	0.00117	CcSEcCtD
Imipramine—Decreased appetite—Fluorouracil—pancreatic cancer	0.000117	0.00117	CcSEcCtD
Imipramine—Mood swings—Doxorubicin—pancreatic cancer	0.000117	0.00117	CcSEcCtD
Imipramine—Diarrhoea—Sunitinib—pancreatic cancer	0.000117	0.00116	CcSEcCtD
Imipramine—Dysgeusia—Docetaxel—pancreatic cancer	0.000117	0.00116	CcSEcCtD
Imipramine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000116	0.00116	CcSEcCtD
Imipramine—Ataxia—Doxorubicin—pancreatic cancer	0.000116	0.00116	CcSEcCtD
Imipramine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000116	0.00116	CcSEcCtD
Imipramine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000115	0.00115	CcSEcCtD
Imipramine—Eosinophilia—Epirubicin—pancreatic cancer	0.000114	0.00114	CcSEcCtD
Imipramine—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000114	0.00114	CcSEcCtD
Imipramine—Dizziness—Sunitinib—pancreatic cancer	0.000113	0.00113	CcSEcCtD
Imipramine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000113	0.00113	CcSEcCtD
Imipramine—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000113	0.00112	CcSEcCtD
Imipramine—Breast disorder—Doxorubicin—pancreatic cancer	0.000111	0.00111	CcSEcCtD
Imipramine—Abdominal pain—Irinotecan—pancreatic cancer	0.000111	0.00111	CcSEcCtD
Imipramine—Body temperature increased—Irinotecan—pancreatic cancer	0.000111	0.00111	CcSEcCtD
Imipramine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000111	0.00111	CcSEcCtD
Imipramine—ABCB1—pancreas—pancreatic cancer	0.000111	0.00692	CbGeAlD
Imipramine—Pancytopenia—Epirubicin—pancreatic cancer	0.000109	0.00109	CcSEcCtD
Imipramine—Vomiting—Sunitinib—pancreatic cancer	0.000108	0.00108	CcSEcCtD
Imipramine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000108	0.00108	CcSEcCtD
Imipramine—Rash—Sunitinib—pancreatic cancer	0.000108	0.00107	CcSEcCtD
Imipramine—Dermatitis—Sunitinib—pancreatic cancer	0.000107	0.00107	CcSEcCtD
Imipramine—Urticaria—Fluorouracil—pancreatic cancer	0.000107	0.00107	CcSEcCtD
Imipramine—Headache—Sunitinib—pancreatic cancer	0.000107	0.00107	CcSEcCtD
Imipramine—Syncope—Docetaxel—pancreatic cancer	0.000107	0.00106	CcSEcCtD
Imipramine—Leukopenia—Docetaxel—pancreatic cancer	0.000107	0.00106	CcSEcCtD
Imipramine—Pollakiuria—Epirubicin—pancreatic cancer	0.000106	0.00106	CcSEcCtD
Imipramine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000106	0.00106	CcSEcCtD
Imipramine—Eosinophilia—Doxorubicin—pancreatic cancer	0.000106	0.00105	CcSEcCtD
Imipramine—Palpitations—Docetaxel—pancreatic cancer	0.000105	0.00105	CcSEcCtD
Imipramine—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000105	0.00105	CcSEcCtD
Imipramine—Weight increased—Epirubicin—pancreatic cancer	0.000105	0.00105	CcSEcCtD
Imipramine—Loss of consciousness—Docetaxel—pancreatic cancer	0.000105	0.00104	CcSEcCtD
Imipramine—Weight decreased—Epirubicin—pancreatic cancer	0.000104	0.00104	CcSEcCtD
Imipramine—Convulsion—Docetaxel—pancreatic cancer	0.000103	0.00103	CcSEcCtD
Imipramine—Hypertension—Docetaxel—pancreatic cancer	0.000103	0.00103	CcSEcCtD
Imipramine—Infestation NOS—Epirubicin—pancreatic cancer	0.000103	0.00102	CcSEcCtD
Imipramine—Drowsiness—Epirubicin—pancreatic cancer	0.000103	0.00102	CcSEcCtD
Imipramine—Infestation—Epirubicin—pancreatic cancer	0.000103	0.00102	CcSEcCtD
Imipramine—Nausea—Sunitinib—pancreatic cancer	0.000101	0.00101	CcSEcCtD
Imipramine—Pancytopenia—Doxorubicin—pancreatic cancer	0.000101	0.00101	CcSEcCtD
Imipramine—Asthenia—Irinotecan—pancreatic cancer	0.000101	0.00101	CcSEcCtD
Imipramine—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000101	0.001	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000101	0.001	CcSEcCtD
Imipramine—Stomatitis—Epirubicin—pancreatic cancer	0.0001	0.000999	CcSEcCtD
Imipramine—Jaundice—Epirubicin—pancreatic cancer	0.0001	0.000999	CcSEcCtD
Imipramine—Dry mouth—Docetaxel—pancreatic cancer	9.91e-05	0.000989	CcSEcCtD
Imipramine—Pollakiuria—Doxorubicin—pancreatic cancer	9.85e-05	0.000982	CcSEcCtD
Imipramine—Asthenia—Gemcitabine—pancreatic cancer	9.82e-05	0.00098	CcSEcCtD
Imipramine—Confusional state—Docetaxel—pancreatic cancer	9.79e-05	0.000977	CcSEcCtD
Imipramine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	9.73e-05	0.000971	CcSEcCtD
Imipramine—Hepatobiliary disease—Epirubicin—pancreatic cancer	9.71e-05	0.000969	CcSEcCtD
Imipramine—Oedema—Docetaxel—pancreatic cancer	9.71e-05	0.000969	CcSEcCtD
Imipramine—Anaphylactic shock—Docetaxel—pancreatic cancer	9.71e-05	0.000969	CcSEcCtD
Imipramine—Weight increased—Doxorubicin—pancreatic cancer	9.7e-05	0.000968	CcSEcCtD
Imipramine—Pruritus—Gemcitabine—pancreatic cancer	9.68e-05	0.000966	CcSEcCtD
Imipramine—Infection—Docetaxel—pancreatic cancer	9.65e-05	0.000963	CcSEcCtD
Imipramine—Weight decreased—Doxorubicin—pancreatic cancer	9.64e-05	0.000962	CcSEcCtD
Imipramine—Diarrhoea—Irinotecan—pancreatic cancer	9.61e-05	0.000959	CcSEcCtD
Imipramine—Agranulocytosis—Epirubicin—pancreatic cancer	9.58e-05	0.000956	CcSEcCtD
Imipramine—Shock—Docetaxel—pancreatic cancer	9.55e-05	0.000953	CcSEcCtD
Imipramine—Nervous system disorder—Docetaxel—pancreatic cancer	9.52e-05	0.00095	CcSEcCtD
Imipramine—Pruritus—Fluorouracil—pancreatic cancer	9.52e-05	0.00095	CcSEcCtD
Imipramine—Thrombocytopenia—Docetaxel—pancreatic cancer	9.51e-05	0.000949	CcSEcCtD
Imipramine—Infestation NOS—Doxorubicin—pancreatic cancer	9.5e-05	0.000948	CcSEcCtD
Imipramine—Infestation—Doxorubicin—pancreatic cancer	9.5e-05	0.000948	CcSEcCtD
Imipramine—Drowsiness—Doxorubicin—pancreatic cancer	9.5e-05	0.000948	CcSEcCtD
Imipramine—Tachycardia—Docetaxel—pancreatic cancer	9.48e-05	0.000946	CcSEcCtD
Imipramine—ABCB1—digestive system—pancreatic cancer	9.45e-05	0.00591	CbGeAlD
Imipramine—Skin disorder—Docetaxel—pancreatic cancer	9.43e-05	0.000941	CcSEcCtD
Imipramine—Diarrhoea—Gemcitabine—pancreatic cancer	9.36e-05	0.000934	CcSEcCtD
Imipramine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	9.32e-05	0.000929	CcSEcCtD
Imipramine—Dizziness—Irinotecan—pancreatic cancer	9.29e-05	0.000927	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—pancreatic cancer	9.26e-05	0.000924	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—pancreatic cancer	9.26e-05	0.000924	CcSEcCtD
Imipramine—Anorexia—Docetaxel—pancreatic cancer	9.26e-05	0.000924	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—pancreatic cancer	9.22e-05	0.00092	CcSEcCtD
Imipramine—Diarrhoea—Fluorouracil—pancreatic cancer	9.21e-05	0.000919	CcSEcCtD
Imipramine—Hypoaesthesia—Epirubicin—pancreatic cancer	9.17e-05	0.000915	CcSEcCtD
Imipramine—Urinary tract disorder—Epirubicin—pancreatic cancer	9.11e-05	0.000908	CcSEcCtD
Imipramine—Urethral disorder—Epirubicin—pancreatic cancer	9.04e-05	0.000902	CcSEcCtD
Imipramine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	8.99e-05	0.000897	CcSEcCtD
Imipramine—Vomiting—Irinotecan—pancreatic cancer	8.93e-05	0.000891	CcSEcCtD
Imipramine—Dizziness—Fluorouracil—pancreatic cancer	8.9e-05	0.000888	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—pancreatic cancer	8.87e-05	0.000885	CcSEcCtD
Imipramine—Rash—Irinotecan—pancreatic cancer	8.86e-05	0.000884	CcSEcCtD
Imipramine—Dermatitis—Irinotecan—pancreatic cancer	8.85e-05	0.000883	CcSEcCtD
Imipramine—Headache—Irinotecan—pancreatic cancer	8.8e-05	0.000878	CcSEcCtD
Imipramine—Insomnia—Docetaxel—pancreatic cancer	8.78e-05	0.000876	CcSEcCtD
Imipramine—Paraesthesia—Docetaxel—pancreatic cancer	8.72e-05	0.00087	CcSEcCtD
Imipramine—Vomiting—Gemcitabine—pancreatic cancer	8.7e-05	0.000868	CcSEcCtD
Imipramine—Somnolence—Docetaxel—pancreatic cancer	8.63e-05	0.000861	CcSEcCtD
Imipramine—Rash—Gemcitabine—pancreatic cancer	8.63e-05	0.000861	CcSEcCtD
Imipramine—Dermatitis—Gemcitabine—pancreatic cancer	8.62e-05	0.00086	CcSEcCtD
Imipramine—Eye disorder—Epirubicin—pancreatic cancer	8.62e-05	0.00086	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—pancreatic cancer	8.6e-05	0.000858	CcSEcCtD
Imipramine—Headache—Gemcitabine—pancreatic cancer	8.57e-05	0.000855	CcSEcCtD
Imipramine—Flushing—Epirubicin—pancreatic cancer	8.56e-05	0.000854	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—pancreatic cancer	8.56e-05	0.000854	CcSEcCtD
Imipramine—Vomiting—Fluorouracil—pancreatic cancer	8.56e-05	0.000854	CcSEcCtD
Imipramine—Dyspepsia—Docetaxel—pancreatic cancer	8.55e-05	0.000853	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—pancreatic cancer	8.53e-05	0.000851	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—pancreatic cancer	8.49e-05	0.000847	CcSEcCtD
Imipramine—Rash—Fluorouracil—pancreatic cancer	8.48e-05	0.000846	CcSEcCtD
Imipramine—Dermatitis—Fluorouracil—pancreatic cancer	8.48e-05	0.000846	CcSEcCtD
Imipramine—Decreased appetite—Docetaxel—pancreatic cancer	8.44e-05	0.000842	CcSEcCtD
Imipramine—Headache—Fluorouracil—pancreatic cancer	8.43e-05	0.000841	CcSEcCtD
Imipramine—Urinary tract disorder—Doxorubicin—pancreatic cancer	8.42e-05	0.000841	CcSEcCtD
Imipramine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	8.38e-05	0.000837	CcSEcCtD
Imipramine—Fatigue—Docetaxel—pancreatic cancer	8.37e-05	0.000835	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—pancreatic cancer	8.37e-05	0.000835	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—pancreatic cancer	8.36e-05	0.000834	CcSEcCtD
Imipramine—Nausea—Irinotecan—pancreatic cancer	8.34e-05	0.000833	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—pancreatic cancer	8.33e-05	0.000831	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—pancreatic cancer	8.31e-05	0.000829	CcSEcCtD
Imipramine—Constipation—Docetaxel—pancreatic cancer	8.3e-05	0.000829	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—pancreatic cancer	8.24e-05	0.000822	CcSEcCtD
Imipramine—Alopecia—Epirubicin—pancreatic cancer	8.15e-05	0.000813	CcSEcCtD
Imipramine—Nausea—Gemcitabine—pancreatic cancer	8.13e-05	0.000811	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—pancreatic cancer	8.08e-05	0.000806	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—pancreatic cancer	8.03e-05	0.000801	CcSEcCtD
Imipramine—Feeling abnormal—Docetaxel—pancreatic cancer	8e-05	0.000798	CcSEcCtD
Imipramine—Nausea—Fluorouracil—pancreatic cancer	7.99e-05	0.000797	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—pancreatic cancer	7.97e-05	0.000795	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—pancreatic cancer	7.95e-05	0.000794	CcSEcCtD
Imipramine—Gastrointestinal pain—Docetaxel—pancreatic cancer	7.94e-05	0.000792	CcSEcCtD
Imipramine—Flushing—Doxorubicin—pancreatic cancer	7.92e-05	0.00079	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—pancreatic cancer	7.92e-05	0.00079	CcSEcCtD
Imipramine—Tension—Epirubicin—pancreatic cancer	7.88e-05	0.000786	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—pancreatic cancer	7.86e-05	0.000784	CcSEcCtD
Imipramine—Nervousness—Epirubicin—pancreatic cancer	7.8e-05	0.000778	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—pancreatic cancer	7.74e-05	0.000772	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—pancreatic cancer	7.71e-05	0.000769	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—pancreatic cancer	7.69e-05	0.000767	CcSEcCtD
Imipramine—Abdominal pain—Docetaxel—pancreatic cancer	7.68e-05	0.000766	CcSEcCtD
Imipramine—Body temperature increased—Docetaxel—pancreatic cancer	7.68e-05	0.000766	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—pancreatic cancer	7.62e-05	0.00076	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—pancreatic cancer	7.56e-05	0.000755	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—pancreatic cancer	7.54e-05	0.000752	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—pancreatic cancer	7.47e-05	0.000746	CcSEcCtD
Imipramine—Ill-defined disorder—Epirubicin—pancreatic cancer	7.45e-05	0.000743	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—pancreatic cancer	7.43e-05	0.000741	CcSEcCtD
Imipramine—Agitation—Epirubicin—pancreatic cancer	7.38e-05	0.000736	CcSEcCtD
Imipramine—Tension—Doxorubicin—pancreatic cancer	7.29e-05	0.000727	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—pancreatic cancer	7.27e-05	0.000726	CcSEcCtD
Imipramine—Malaise—Epirubicin—pancreatic cancer	7.24e-05	0.000722	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—pancreatic cancer	7.21e-05	0.00072	CcSEcCtD
Imipramine—Syncope—Epirubicin—pancreatic cancer	7.2e-05	0.000718	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—pancreatic cancer	7.18e-05	0.000717	CcSEcCtD
Imipramine—Palpitations—Epirubicin—pancreatic cancer	7.09e-05	0.000708	CcSEcCtD
Imipramine—Loss of consciousness—Epirubicin—pancreatic cancer	7.05e-05	0.000704	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—pancreatic cancer	7e-05	0.000698	CcSEcCtD
Imipramine—Asthenia—Docetaxel—pancreatic cancer	6.97e-05	0.000695	CcSEcCtD
Imipramine—Convulsion—Epirubicin—pancreatic cancer	6.95e-05	0.000694	CcSEcCtD
Imipramine—Hypertension—Epirubicin—pancreatic cancer	6.93e-05	0.000691	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—pancreatic cancer	6.89e-05	0.000688	CcSEcCtD
Imipramine—Pruritus—Docetaxel—pancreatic cancer	6.87e-05	0.000686	CcSEcCtD
Imipramine—Agitation—Doxorubicin—pancreatic cancer	6.82e-05	0.000681	CcSEcCtD
Imipramine—Anxiety—Epirubicin—pancreatic cancer	6.81e-05	0.000679	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	6.79e-05	0.000677	CcSEcCtD
Imipramine—Discomfort—Epirubicin—pancreatic cancer	6.75e-05	0.000674	CcSEcCtD
Imipramine—Malaise—Doxorubicin—pancreatic cancer	6.7e-05	0.000668	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—pancreatic cancer	6.68e-05	0.000667	CcSEcCtD
Imipramine—Syncope—Doxorubicin—pancreatic cancer	6.66e-05	0.000664	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—pancreatic cancer	6.65e-05	0.000663	CcSEcCtD
Imipramine—Diarrhoea—Docetaxel—pancreatic cancer	6.64e-05	0.000663	CcSEcCtD
Imipramine—Confusional state—Epirubicin—pancreatic cancer	6.6e-05	0.000659	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—pancreatic cancer	6.56e-05	0.000655	CcSEcCtD
Imipramine—Oedema—Epirubicin—pancreatic cancer	6.55e-05	0.000654	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—pancreatic cancer	6.55e-05	0.000654	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—pancreatic cancer	6.53e-05	0.000651	CcSEcCtD
Imipramine—Infection—Epirubicin—pancreatic cancer	6.51e-05	0.000649	CcSEcCtD
Imipramine—Shock—Epirubicin—pancreatic cancer	6.44e-05	0.000643	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—pancreatic cancer	6.43e-05	0.000642	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—pancreatic cancer	6.42e-05	0.000641	CcSEcCtD
Imipramine—Dizziness—Docetaxel—pancreatic cancer	6.42e-05	0.000641	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—pancreatic cancer	6.41e-05	0.00064	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—pancreatic cancer	6.41e-05	0.00064	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—pancreatic cancer	6.39e-05	0.000638	CcSEcCtD
Imipramine—Skin disorder—Epirubicin—pancreatic cancer	6.36e-05	0.000635	CcSEcCtD
Imipramine—Hyperhidrosis—Epirubicin—pancreatic cancer	6.33e-05	0.000632	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—pancreatic cancer	6.3e-05	0.000629	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	6.28e-05	0.000626	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—pancreatic cancer	6.25e-05	0.000623	CcSEcCtD
Imipramine—Anorexia—Epirubicin—pancreatic cancer	6.24e-05	0.000623	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—pancreatic cancer	6.18e-05	0.000617	CcSEcCtD
Imipramine—Vomiting—Docetaxel—pancreatic cancer	6.17e-05	0.000616	CcSEcCtD
Imipramine—Rash—Docetaxel—pancreatic cancer	6.12e-05	0.000611	CcSEcCtD
Imipramine—Dermatitis—Docetaxel—pancreatic cancer	6.12e-05	0.00061	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—pancreatic cancer	6.11e-05	0.00061	CcSEcCtD
Imipramine—Headache—Docetaxel—pancreatic cancer	6.08e-05	0.000607	CcSEcCtD
Imipramine—Oedema—Doxorubicin—pancreatic cancer	6.06e-05	0.000605	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—pancreatic cancer	6.06e-05	0.000605	CcSEcCtD
Imipramine—Infection—Doxorubicin—pancreatic cancer	6.02e-05	0.000601	CcSEcCtD
Imipramine—Shock—Doxorubicin—pancreatic cancer	5.96e-05	0.000595	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—pancreatic cancer	5.94e-05	0.000593	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.93e-05	0.000592	CcSEcCtD
Imipramine—Insomnia—Epirubicin—pancreatic cancer	5.92e-05	0.000591	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—pancreatic cancer	5.92e-05	0.00059	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—pancreatic cancer	5.89e-05	0.000587	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—pancreatic cancer	5.88e-05	0.000587	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—pancreatic cancer	5.86e-05	0.000585	CcSEcCtD
Imipramine—Somnolence—Epirubicin—pancreatic cancer	5.82e-05	0.000581	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—pancreatic cancer	5.78e-05	0.000576	CcSEcCtD
Imipramine—Nausea—Docetaxel—pancreatic cancer	5.77e-05	0.000576	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—pancreatic cancer	5.77e-05	0.000575	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—pancreatic cancer	5.69e-05	0.000568	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	5.66e-05	0.000564	CcSEcCtD
Imipramine—Fatigue—Epirubicin—pancreatic cancer	5.65e-05	0.000563	CcSEcCtD
Imipramine—Constipation—Epirubicin—pancreatic cancer	5.6e-05	0.000559	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—pancreatic cancer	5.48e-05	0.000547	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—pancreatic cancer	5.44e-05	0.000543	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—pancreatic cancer	5.4e-05	0.000539	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—pancreatic cancer	5.39e-05	0.000538	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—pancreatic cancer	5.36e-05	0.000534	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—pancreatic cancer	5.34e-05	0.000532	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—pancreatic cancer	5.27e-05	0.000526	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	5.23e-05	0.000522	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—pancreatic cancer	5.23e-05	0.000521	CcSEcCtD
Imipramine—Urticaria—Epirubicin—pancreatic cancer	5.2e-05	0.000519	CcSEcCtD
Imipramine—Constipation—Doxorubicin—pancreatic cancer	5.18e-05	0.000517	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—pancreatic cancer	5.18e-05	0.000517	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—pancreatic cancer	5.18e-05	0.000517	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—pancreatic cancer	4.99e-05	0.000498	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.96e-05	0.000495	CcSEcCtD
Imipramine—Urticaria—Doxorubicin—pancreatic cancer	4.81e-05	0.00048	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—pancreatic cancer	4.79e-05	0.000478	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—pancreatic cancer	4.79e-05	0.000478	CcSEcCtD
Imipramine—Asthenia—Epirubicin—pancreatic cancer	4.7e-05	0.000469	CcSEcCtD
Imipramine—Pruritus—Epirubicin—pancreatic cancer	4.63e-05	0.000462	CcSEcCtD
Imipramine—Diarrhoea—Epirubicin—pancreatic cancer	4.48e-05	0.000447	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—pancreatic cancer	4.35e-05	0.000434	CcSEcCtD
Imipramine—Dizziness—Epirubicin—pancreatic cancer	4.33e-05	0.000432	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—pancreatic cancer	4.29e-05	0.000428	CcSEcCtD
Imipramine—Vomiting—Epirubicin—pancreatic cancer	4.16e-05	0.000416	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—pancreatic cancer	4.15e-05	0.000414	CcSEcCtD
Imipramine—Rash—Epirubicin—pancreatic cancer	4.13e-05	0.000412	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—pancreatic cancer	4.13e-05	0.000412	CcSEcCtD
Imipramine—Headache—Epirubicin—pancreatic cancer	4.1e-05	0.000409	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—pancreatic cancer	4.01e-05	0.0004	CcSEcCtD
Imipramine—Nausea—Epirubicin—pancreatic cancer	3.89e-05	0.000388	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—pancreatic cancer	3.85e-05	0.000385	CcSEcCtD
Imipramine—Rash—Doxorubicin—pancreatic cancer	3.82e-05	0.000381	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—pancreatic cancer	3.82e-05	0.000381	CcSEcCtD
Imipramine—Headache—Doxorubicin—pancreatic cancer	3.8e-05	0.000379	CcSEcCtD
Imipramine—Nausea—Doxorubicin—pancreatic cancer	3.6e-05	0.000359	CcSEcCtD
Imipramine—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	2.32e-06	2.99e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	2.31e-06	2.98e-05	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.31e-06	2.98e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	2.3e-06	2.97e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	2.3e-06	2.96e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KRAS—pancreatic cancer	2.3e-06	2.96e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	2.29e-06	2.95e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.29e-06	2.95e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	2.28e-06	2.95e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	2.28e-06	2.94e-05	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.27e-06	2.93e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—SRC—pancreatic cancer	2.27e-06	2.93e-05	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	2.27e-06	2.93e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	2.27e-06	2.92e-05	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	2.26e-06	2.92e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	2.26e-06	2.91e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—pancreatic cancer	2.26e-06	2.91e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—pancreatic cancer	2.26e-06	2.91e-05	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	2.25e-06	2.91e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	2.25e-06	2.91e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CASP3—pancreatic cancer	2.25e-06	2.9e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	2.24e-06	2.89e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	2.23e-06	2.88e-05	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	2.23e-06	2.88e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.23e-06	2.87e-05	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	2.23e-06	2.87e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	2.21e-06	2.85e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	2.21e-06	2.85e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.21e-06	2.85e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	2.21e-06	2.84e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—PIK3CA—pancreatic cancer	2.2e-06	2.84e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	2.2e-06	2.84e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	2.19e-06	2.83e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	2.19e-06	2.83e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CCND1—pancreatic cancer	2.19e-06	2.82e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.19e-06	2.82e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	2.18e-06	2.82e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	2.18e-06	2.81e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	2.18e-06	2.81e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	2.17e-06	2.8e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	2.17e-06	2.8e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.17e-06	2.8e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	2.17e-06	2.79e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	2.17e-06	2.79e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	2.16e-06	2.79e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.16e-06	2.79e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—pancreatic cancer	2.16e-06	2.79e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	2.16e-06	2.79e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—pancreatic cancer	2.16e-06	2.78e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	2.16e-06	2.78e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—pancreatic cancer	2.16e-06	2.78e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	2.15e-06	2.78e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	2.15e-06	2.78e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.15e-06	2.77e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	2.15e-06	2.77e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	2.13e-06	2.75e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—pancreatic cancer	2.13e-06	2.75e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	2.13e-06	2.75e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—APOE—pancreatic cancer	2.13e-06	2.74e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.13e-06	2.74e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MMP9—pancreatic cancer	2.12e-06	2.74e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	2.12e-06	2.73e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	2.12e-06	2.73e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—pancreatic cancer	2.11e-06	2.73e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	2.11e-06	2.73e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—pancreatic cancer	2.11e-06	2.72e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	2.11e-06	2.72e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	2.11e-06	2.72e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	2.11e-06	2.72e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	2.1e-06	2.71e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.1e-06	2.71e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	2.1e-06	2.71e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	2.09e-06	2.7e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	2.09e-06	2.69e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	2.08e-06	2.69e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	2.08e-06	2.68e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	2.08e-06	2.68e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	2.07e-06	2.67e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	2.06e-06	2.66e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	2.06e-06	2.66e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	2.06e-06	2.66e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	2.06e-06	2.65e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	2.05e-06	2.65e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	2.05e-06	2.64e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—pancreatic cancer	2.04e-06	2.63e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	2.04e-06	2.63e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MYC—pancreatic cancer	2.04e-06	2.63e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	2.03e-06	2.62e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	2.03e-06	2.61e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	2.02e-06	2.61e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	2.02e-06	2.61e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	2.02e-06	2.61e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.02e-06	2.6e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.01e-06	2.6e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SRC—pancreatic cancer	1.99e-06	2.57e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.99e-06	2.57e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	1.99e-06	2.57e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.98e-06	2.56e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.98e-06	2.55e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	1.96e-06	2.53e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SRC—pancreatic cancer	1.96e-06	2.53e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SRC—pancreatic cancer	1.95e-06	2.52e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	1.95e-06	2.52e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SRC—pancreatic cancer	1.95e-06	2.51e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	1.94e-06	2.51e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	1.94e-06	2.5e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	1.93e-06	2.49e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SRC—pancreatic cancer	1.93e-06	2.49e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—STAT3—pancreatic cancer	1.92e-06	2.48e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	1.92e-06	2.48e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.92e-06	2.48e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRAS—pancreatic cancer	1.92e-06	2.47e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	1.92e-06	2.47e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	1.92e-06	2.47e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	1.91e-06	2.47e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	1.91e-06	2.46e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—pancreatic cancer	1.91e-06	2.46e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—pancreatic cancer	1.9e-06	2.46e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	1.9e-06	2.45e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	1.9e-06	2.45e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	1.89e-06	2.44e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	1.89e-06	2.44e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—STAT3—pancreatic cancer	1.89e-06	2.44e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	1.89e-06	2.43e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.89e-06	2.43e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRAS—pancreatic cancer	1.88e-06	2.43e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	1.88e-06	2.43e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	1.88e-06	2.43e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	1.88e-06	2.42e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	1.88e-06	2.42e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	1.88e-06	2.42e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	1.87e-06	2.41e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	1.87e-06	2.41e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.87e-06	2.41e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.87e-06	2.41e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	1.86e-06	2.4e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	1.85e-06	2.39e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	1.85e-06	2.39e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.85e-06	2.39e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	1.85e-06	2.38e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.84e-06	2.38e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	1.83e-06	2.37e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.83e-06	2.35e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	1.8e-06	2.32e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	1.79e-06	2.31e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.79e-06	2.31e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.78e-06	2.3e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PIK3CA—pancreatic cancer	1.77e-06	2.28e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.76e-06	2.27e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MYC—pancreatic cancer	1.75e-06	2.26e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.75e-06	2.26e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	1.75e-06	2.26e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MYC—pancreatic cancer	1.75e-06	2.26e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1.75e-06	2.25e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	1.74e-06	2.25e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MYC—pancreatic cancer	1.74e-06	2.25e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	1.74e-06	2.24e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.74e-06	2.24e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.73e-06	2.23e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MYC—pancreatic cancer	1.73e-06	2.23e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	1.72e-06	2.22e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	1.72e-06	2.22e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	1.72e-06	2.22e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.72e-06	2.22e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	1.72e-06	2.22e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.72e-06	2.22e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	1.72e-06	2.22e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EGFR—pancreatic cancer	1.72e-06	2.21e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	1.71e-06	2.21e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	1.71e-06	2.2e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	1.69e-06	2.18e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.69e-06	2.18e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	1.68e-06	2.17e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—pancreatic cancer	1.68e-06	2.17e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—pancreatic cancer	1.68e-06	2.17e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—pancreatic cancer	1.67e-06	2.16e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	1.66e-06	2.14e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.65e-06	2.13e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.65e-06	2.12e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—APOE—pancreatic cancer	1.64e-06	2.12e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.63e-06	2.1e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.62e-06	2.1e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—pancreatic cancer	1.62e-06	2.09e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	1.62e-06	2.09e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	1.62e-06	2.08e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	1.61e-06	2.08e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	1.6e-06	2.06e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	1.6e-06	2.06e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—pancreatic cancer	1.59e-06	2.05e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	1.59e-06	2.05e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	1.59e-06	2.05e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	1.59e-06	2.05e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—pancreatic cancer	1.57e-06	2.02e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	1.52e-06	1.96e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	1.52e-06	1.96e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.52e-06	1.96e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.5e-06	1.93e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.49e-06	1.93e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	1.49e-06	1.92e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	1.49e-06	1.92e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	1.48e-06	1.92e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.48e-06	1.91e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	1.48e-06	1.91e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.47e-06	1.9e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.47e-06	1.89e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	1.47e-06	1.89e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.46e-06	1.89e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.46e-06	1.88e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—pancreatic cancer	1.45e-06	1.87e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	1.44e-06	1.86e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—pancreatic cancer	1.44e-06	1.86e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—pancreatic cancer	1.44e-06	1.85e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—pancreatic cancer	1.43e-06	1.85e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.43e-06	1.84e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—pancreatic cancer	1.42e-06	1.83e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	1.41e-06	1.82e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	1.41e-06	1.82e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	1.4e-06	1.81e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.4e-06	1.81e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.38e-06	1.78e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—pancreatic cancer	1.38e-06	1.78e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	1.37e-06	1.77e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	1.37e-06	1.77e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	1.36e-06	1.75e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	1.35e-06	1.74e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	1.34e-06	1.73e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.3e-06	1.68e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.27e-06	1.64e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—pancreatic cancer	1.24e-06	1.6e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.24e-06	1.6e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.22e-06	1.57e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—pancreatic cancer	1.22e-06	1.57e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—pancreatic cancer	1.22e-06	1.57e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	1.21e-06	1.56e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	1.21e-06	1.56e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	1.2e-06	1.54e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	1.19e-06	1.54e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	1.15e-06	1.48e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.13e-06	1.46e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.12e-06	1.45e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.12e-06	1.45e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.06e-06	1.37e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—pancreatic cancer	9.81e-07	1.27e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—pancreatic cancer	9.4e-07	1.21e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—pancreatic cancer	9.17e-07	1.18e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	8.96e-07	1.16e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—pancreatic cancer	8.64e-07	1.12e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—pancreatic cancer	7.32e-07	9.45e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	6.92e-07	8.92e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—pancreatic cancer	5.65e-07	7.29e-06	CbGpPWpGaD
